News | Image Guided Radiation Therapy (IGRT) | July 03, 2017

First New York Metropolitan Hospital Treats Cancer Patients With Accuray Radixact System

Advanced radiation therapy system dramatically improves precision, efficiency and safety while minimizing side effects

First New York Metropolitan Hospital Treats Cancer Patients With Accuray Radixact System

July 3, 2017 — Accuray Inc. and Montefiore Einstein Center for Cancer Care (MECCC), part of the Montefiore Health System (MHS), announced that Montefiore doctors have treated the first cancer patients in New York with the advanced Radixact Treatment Delivery System. The system was designed to deliver image-guided intensity-modulated (IG-IMRT) radiation therapy, an extremely precise form of radiation therapy. Montefiore is the only hospital in New York State, and in the greater New York area, to have this equipment.

The Radixact System is the next-generation TomoTherapy platform developed to enable doctors to more efficiently and effectively deliver precise radiation treatments to more patients with cancer every day. What makes the Radixact technology different from conventional radiation systems is the integration of a computed tomography (CT) scanner with the radiation therapy delivery system. The built-in CT scanner performs daily imaging before each treatment session to determine the shape and position of the tumor. This allows for accurate and precise tumor targeting, while reducing the radiation dose to normal, healthy tissue. Only then, is radiation delivered from 360 degrees around the patient's body allowing for treatment of any target, irrespective of its length. 

Daily pretreatment imaging, coupled with the system's Accuray Precision Treatment Planning System and PreciseART Adaptive Radiation Therapy software, informs precise treatment planning and mid-course decision-making, so clinical teams can instantly adapt therapy to:

  • Changes in tumor size, shape and location; and
  • Subtle changes in the location of organs and other healthy tissue, due to weight gain or loss

Identifying and correcting for any variations in patient positioning, as well as biological changes, ensures the continued precision and safe delivery of the radiation dose to the target area, resulting in fewer long term side effects.

The Radixact System is capable of treating all standard radiation therapy indications including breast, head and neck, lung and prostate cancers, in addition to complex treatments such as total marrow irradiation. The Montefiore patients were treated for prostate cancer, and plans are also in place to use the system for patients with Ob/Gyn-related cancers and head and neck cancers, as these often require alterations to therapy mid-course due to changes in tumor size, location and individual weight.

"We could not be more thrilled to have this amazing technology here at Montefiore, along with the clinical expertise to guide its use," said Shalom Kalnicki, M.D., FACRO, professor and chair, Department of Radiation Oncology, Montefiore Einstein Center for Cancer Care and Albert Einstein College of Medicine. "We know the ability to adapt the radiation dose to the actual target and normal tissue position and shape is key to the future of radiation therapy. This technology is so sophisticated it can streamline treatment so cures are more frequent and patients are better protected from side effects they have suffered in the past. The Radixact System is an exciting step forward solidifying the Montefiore Einstein Center for Cancer Care's place on the frontier of cancer treatment."

According to the Centers for Disease Control and Prevention (CDC), the state of New York has the third highest cancer rate in the United States. More than 105,000 people in New York are diagnosed with cancer each year, or approximately 287 people each day. Innovations such as the Radixact System are helping to make it possible for people who are diagnosed with cancer to live longer with a better quality of life than was previously possible.

For more information: www.accuray.com

Related Content

Hippocampal Sparing Prevents Whole-Brain Radiotherapy Cognitive Side Effects
News | Radiation Therapy | October 23, 2018
Whole-brain radiotherapy can be delivered more safely to patients with brain metastases by avoiding the hippocampus,...
Artificial intelligence (AI) will not force specialists in radiation oncology from their jobs but rather make them better at the jobs only they can do, said speakers at the annual meeting of the American Society of Radiation Oncology (ASTRO) in San Antonio, Texas.
Feature | Artificial Intelligence | October 22, 2018 | By Greg Freiherr
Artificial intelligence (AI) will not force specialists in radiation oncology from their jobs but rather make them be
News | Prostate Cancer | October 22, 2018
The first report of a large, international clinical trial shows that, for men who show signs of...

Image courtesy of Vital Images

News | ASTRO | October 22, 2018
Treatment of renal cell carcinoma with stereotactic radiation therapy is as safe and effective for patients with one
Fewer, larger individual doses of radiation lead to similar adverse effects to normal tissue after 10 years as with conventional radiation therapy for early breast cancer
News | ASTRO | October 22, 2018
In a 10-year study of women who received radiation therapy to treat early-stage breast cancer, those receiving fewer,
Patients whose cancer has not spread far past the lungs may benefit from targeting tumor sites with radiation or surgery after initial treatment, according to ASTRO study
News | ASTRO | October 21, 2018
Adding radiation therapy or surgery to systemic therapy for stage IV lung cancer patients whose cancer has spread to
DCIS, ductal carcinoma in situ, radiation therapy, survival benefit, Brigham and Women's Hospital study

Image courtesy of Barco

News | ASTRO | October 21, 2018
A subset of patients with low-risk breast cancer is highly unlikely to see cancer return following breast conservatio
The Elekta Unity with 1.5T MRI embedded as a targeting system appeared at the annual meeting of the American Society of Radiation Oncology (ASTRO) in San Antonio, Texas. The system is being sold in Europe and could soon enter the U.S. marketplace. (Photo courtesy of Elekta)

The Elekta Unity with 1.5T MRI embedded as a targeting system appeared at the annual meeting of the American Society of Radiation Oncology (ASTRO) in San Antonio, Texas. The system is being sold in Europe and could soon enter the U.S. marketplace. (Photo courtesy of Elekta)

Feature | ASTRO | October 20, 2018 | By Greg Freiherr
A linear accelerator combined with high-field MRI could soon be on the U.S. market. If U.S.
The Aquilion Precision CT system from Canon offers very high resolution imaging, which may aid in cancer detection and improved treatment planning in radiation oncology. #ASTRO2018 #ASTRO #ASTRO18

The Aquilion Precision CT system from Canon offers very high resolution imaging, which may aid in cancer detection and improved treatment planning in radiation oncology. 

News | Computed Tomography (CT) | October 19, 2018
October 19, 2018 – At the 2018 American Society of...
IBA's Proteus system and proton therapy solutions will be discussed at ASTRO 2018. #ASTRO18 #ASTRO #ASTRO2018
News | Proton Therapy | October 19, 2018
October 19, 2018 – IBA (Ion Beam Applications S.A.) is sharing how hospitals can secure performance, investment and t